Transaction Advisory and Consulting
YAFO provides professional services in asset licensing, M&A, fundraising, buy-side research, commercial assessment, and pipeline strategy for global and Asian biopharma and medtech companies.
YAFO CAPITAL
Bridging Global Innovation and Life Sciences Partnerships
Bridging Global Biopharma, Medtech, and Asia
YAFO Capital
Headquartered in Shanghai, YAFO Capital is a boutique investment and advisory platform focused on cross-border transactions and global innovation partnerships in life sciences. With a global team and partner network across China, the United States, Europe, Japan, South Korea, and Southeast Asia, YAFO Capital is dedicated to connecting Asian and global biopharma, medtech, and investment ecosystems. YAFO Capital’s business spans transaction advisory and consulting, NewCo incubation, investment fund management, and industry partnering platforms. Leveraging deep sector knowledge, extensive transaction execution experience, and a broad global partner network, YAFO supports clients throughout the full transaction lifecycle, including strategy development, asset screening, deal planning, due diligence, negotiation, execution, and closing.
Our Businesses
Transaction Advisory and Consulting
YAFO provides professional services in asset licensing, M&A, fundraising, buy-side research, commercial assessment, and pipeline strategy for global and Asian biopharma and medtech companies.
YAFO Fund
YAFO invests in innovative life sciences companies and high-potential assets along with strategic industry partners.
NewCo Incubation and Innovation Collaboration
Through co-development, investment, and clinical execution support, YAFO helps global innovative assets accelerate their clinical process and maximize value through licensing, M&A, or capital partnerships
ACCESS ASIA Partnering Platform
Through virtual roadshows, in-person forums, and global industry events, ACCESS ASIA connects Asian and global pharmaceutical companies, biotech companies, investors, and strategic partners to facilitate cross-border business development and transactions.
Global Network
YAFO Capital has established a global business network across China, the United States, Europe, Japan, South Korea, and Southeast Asia. Our team and partners are active in major life sciences innovation hubs, enabling clients to efficiently access key decision-makers, strategic partners, investors, and potential transaction counterparties.
Our Team Members
Sean Jiang, CFA
Founder & CEO
20 years of Wall Street experience, banking & investment of technologies
Fan Zheng
Managing Partner, Execution
Extensive involvement and expertise in 30+ global life science licensing & cross border financial transactions
Victor Ye
Managing Partner, China Division
25+ years’ experience in Pharmaceutical industry, including the supply Chain as well as commercial and Business development
William Yao
Managing Partner, MedTech
30 years+ healthcare experience, including 7+ years in AstraZeneca China
Grace Hu, PhD, MBA
Partner, US
20+ years of experience in the healthcare industry covering drug development, sales force effectiveness, finance, strategic planning and BD
News
YAFO Transactions | CrystalO enters collaboration with Almirall for the discovery and development of novel small molecules in medical dermatology
View more →
YAFO Capital Managing Partner Fan Zheng Speaks at 2026 thebell Pharmaceutical & Bio Forum
Seoul, South Korea — April 2026 — YAFO Capital participated in the 2026 thebell Pharmaceutical & Bio Forum, held on April 27 at The Plaza Hotel in Seoul. The forum, held under the theme “K-Bio Global Deal-Making and Investment Strategies,” brought together global pharmaceutical companies, biotech executives, venture investors, and Korean pharmaceutical and biotech companies to discuss collaboration and investment opportunities.
View more →
Pipeline Outlook for 17 Global Pharma Leaders: Strategic Layout, R&D Initiatives, and BD Implications
We have conducted a comprehensive review of the top 17 global MNCs, analyzing product portfolios, market iterations, R&D pipelines, deal activity, and patent positioning. Leveraging big data analytics and case studies, this report highlights emerging R&D priorities, deal-making needs, and the likely sources of the next blockbuster assets.
View more →